CRUCELL AND DSM ANNOUNCE PER.C6 LICENSING AGREEMENT WITH CHIRON

Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and allied contract manufacturer DSM Biologics announced today that they have signed a PER.C6 research license agreement for recombinant protein production with Chiron Corporation. This new agreement allows Chiron to evaluate the PER.C6 cell line for use in the manufacturing of Chiron´s prophylactic hepatitis C vaccine, which is currently in phase I clinical trials.

Tiscali (http://finanzen.tiscali.de/tiscali2/news.htm?u=0&k=0&id=23931280)